AASLD Review | Emerging Therapies for Metabolism-Related Fatty Liver Disease: Ecolgnetide, Saroglitazar, Retatrutide, etc.

AASLD Review | Emerging Therapies for Metabolism-Related Fatty Liver Disease: Ecolgnetide, Saroglitazar, Retatrutide, etc.

2023.12.20
Metabolism-related fatty liver disease (MAFLD) has become the leading cause of global chronic liver disease, yet there are currently no targeted and effective treatments. In recent years, the development of new drugs for MAFLD and metabolism-related fatty liver hepatitis (MASH) has been a mix of optimism and concern. The 2023 American Association for the Study of Liver Diseases (AASLD) Annual Meeting has selected six studies on novel MAFLD therapies from numerous abstract submissions. "Novel Therapeutic Approaches for MASH" will showcase relevant content, and interested readers can tune in on November 13th at 8:30 AM local time.
Dr. Chao Wu and Dr. Jie Li’s Team at Nanjing Drum Tower Hospital Focus on Non-invasive Diagnosis, Risk Factors, and Treatment Management of Hepatitis

Dr. Chao Wu and Dr. Jie Li’s Team at Nanjing Drum Tower Hospital Focus on Non-invasive Diagnosis, Risk Factors, and Treatment Management of Hepatitis

2023.12.20
Hepatitis B virus (HBV) infection is a widespread global health issue. According to the World Health Organization, as of 2019, approximately 296 million people globally suffer from chronic HBV infection, with around 1.5 million new infections annually, leading to 820,000 deaths due to HBV-related complications. Data from the Chinese Center for Disease Control and Prevention indicates that around 86 million people in China have chronic HBV infection. Simultaneously, with changes in lifestyle and dietary habits, metabolic-associated fatty liver disease (MAFLD) has become the most common chronic liver disease globally, affecting approximately one-third of the world's population. In Asia, the prevalence of MAFLD has been steadily rising, increasing from 25.28% between 1999 and 2005 to 33.90% between 2012 and 2017.
Professor Lili Liu and Associate Researcher Xuejing Zou’s Team: Targeting Macrophages May Offer New Treatment Strategies for IInhibiting MASH Progres

Professor Lili Liu and Associate Researcher Xuejing Zou’s Team: Targeting Macrophages May Offer New Treatment Strategies for IInhibiting MASH Progres

2023.12.20
The AASLD 2023 Annual Meeting, hosted by the American Association for the Study of Liver Diseases, recently concluded in Boston, USA. A team led by Professor Lili Liu and Associate Researcher Xuejing Zou from Southern Medical University's Nanfang Hospital in China, including Physician Ziyong Zhang, presented their research in the field of Metabolism-Associated Steatohepatitis (MASH) during the conference's oral presentations (Oral 38). Their study suggests that targeting macrophages may offer a new strategy to inhibit the progression of MASH to liver fibrosis. Dr. Ziyong Zhang was invited to introduce their research at the conference and share his experiences and insights.
ESMO Hot Topics Update: New Developments in Precision Diagnosis and Treatment with Talazoparib

ESMO Hot Topics Update: New Developments in Precision Diagnosis and Treatment with Talazoparib

2023.12.01
At this year's recently concluded ESMO conference, new developments related to the PARP inhibitor talazoparib in precision diagnosis and treatment were announced. Precision diagnosis has become a leading trend in the field of prostate cancer, and biomarker research is receiving increasing attention. In this context, this publication invited Professor Guiming Zhang from Qingdao University Affiliated Hospital, a well-known young expert in the field of prostate cancer, for an in-depth interview to explain the three new developments related to talazoparib's precision treatment recently announced at ESMO. Here, we provide a summary of the interview for the readers.
ESMO Exclusive Interview | Professor HuiyanLuo : Significant Efficacy of the Combination of Anti-PD-L1/TGF-βRII Dual-Target Antibody SHR-1701 with Bevacizumab in the Treatment of Advanced Solid Tumors

ESMO Exclusive Interview | Professor HuiyanLuo : Significant Efficacy of the Combination of Anti-PD-L1/TGF-βRII Dual-Target Antibody SHR-1701 with Bevacizumab in the Treatment of Advanced Solid Tumors

2023.12.01
The 2023 European Society for Medical Oncology (ESMO) Annual Meeting took place from October 20th to 24th in Madrid, Spain. The Oncology Insights Reporting Team delved deep into the front lines to witness international advancements and to witness the progress of China's anti-tumor efforts on the global stage. Professor Huiyan Luo from Sun Yat-sen University Cancer Center presented a crucial oral presentation (Abstract ID: 1026MO) at this conference. In this on-site interview, Professor Huiyan Luo shared insights into the study of the treatment of advanced solid tumors using the dual-target antibody SHR-1701, which targets PD-L1 and TGF-βRII, in combination with the VEGF inhibitor bevacizumab, as well as her thoughts on future directions for the treatment of advanced tumors. This article compiles the relevant content for readers.
IDWeek Interview | Dr. Shields: Real-World Study on the Efficacy of Two Generation BL-BLI Combination Therapy for MDR-PA

IDWeek Interview | Dr. Shields: Real-World Study on the Efficacy of Two Generation BL-BLI Combination Therapy for MDR-PA

2023.11.30
Ceftolozane-tazobactam is a new BL-BLI combination drug, and ceftolozane is a third-generation cephalosporin antibiotic, and tazobactam is a beta-lactamase inhibitor. At the recent 2023 IDWeek in the United States, Dr. Ryan K. Shields from the University of Pittsburgh presented a real-world observational study assessing the effectiveness of ceftolozane-tazobactam compared to ceftazidime-avibactam in treating multidrug-resistant Pseudomonas aeruginosa (MDR-PA). He shared his insights in an interview with " Infectious Disease Frontline".
Dr. Thomas L. Holland：Careful consideration when selecting clinical outcomes brings more possibilities to clinical trials of bacterial diseases

Dr. Thomas L. Holland：Careful consideration when selecting clinical outcomes brings more possibilities to clinical trials of bacterial diseases

2023.11.30
Staphylococcus aureus bacteremia is a major cause of bloodstream infections, and hospital-acquired bacterial pneumonia is often caused by multidrug-resistant bacteria. And developing new antibiotics requires patient-centered clinical outcomes. How to conduct a patient-centered benefit-risk assessment in the design, analysis, and interpretation of clinical trials, so that more bacterial clinical studies can achieve the expected efficacy? At the recently Infectious Disease Week (IDWeek 2023), "Infectious Disease Frontline" invited Dr. Thomas L. Holland from Duke University Medical Center to introduce the practical application and potential challenges of DOOR research on ordinal outcome, and shared its importance to future clinical trials and treatment plans.